2022
Comfort Measures Only in Myocardial Infarction: Prevalence of This Status, Change Over Time, and Predictors From a Nationwide Study
Haghighat L, Reinhardt SW, Saly DL, Lu D, Matsouaka RA, Wang TY, Desai NR. Comfort Measures Only in Myocardial Infarction: Prevalence of This Status, Change Over Time, and Predictors From a Nationwide Study. Circulation Cardiovascular Quality And Outcomes 2022, 15: e007610. PMID: 35041476, DOI: 10.1161/circoutcomes.120.007610.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionChest Pain-MI RegistryACTION Registry-GWTGHospital major bleedingIndependent patient characteristicsRetrospective cohort studyHigh-risk patientsMortality risk scoreAggressive initial managementHigh mortality rateMedian odds ratioCMO patientsHospital complicationsMajor bleedingCardiogenic shockCohort studyDiagnostic catheterizationMost patientsNonprivate insurancePatient characteristicsInitial managementProcedural complicationsSuch patientsMale gender
2021
Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial
Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLOS ONE 2021, 16: e0256338. PMID: 34411158, PMCID: PMC8376053, DOI: 10.1371/journal.pone.0256338.Peer-Reviewed Original ResearchConceptsAbsolute risk reductionPrior stroke/TIAStroke/TIASystemic embolismAtrial fibrillationMajor bleedingRE-LYOlder patientsLong-Term Anticoagulation Therapy (RE-LY) trialStroke/systemic embolismGood renal functionHigh-risk patientsHistory of diabetesRE-LY trialPatient-level dataShared decision makingMedian followRenal functionHeart failureHeavier patientsMultivariable modelDabigatranIndividual patientsTreatment groupsIndividualized estimates